Amgen shares new Tavneos analysis in effort to resolve FDA dispute news2026-07-24T18:07:30+00:00July 24th, 2026|Endpoints News|
Ipsen’s Bylvay fails key trial in children with rare liver diseasenews2026-07-24T15:32:16+00:00July 24th, 2026|Endpoints News|
Biogen’s Alzheimer’s data spur excitement, confusion about tau-targeting drugsnews2026-07-24T14:30:06+00:00July 24th, 2026|Endpoints News|
Novo asks court to block Lilly ads; Merck strikes HIV PrEP dealnews2026-07-24T14:08:57+00:00July 24th, 2026|Endpoints News|
CHMP recommends Minoryx’s ALD drug, rejects Zevra’s Meplyffanews2026-07-24T13:23:37+00:00July 24th, 2026|Endpoints News|
Michael Ehlers joins Formation Bio to lead R&D; Black Diamond co-founder dies at 67news2026-07-24T11:00:10+00:00July 24th, 2026|Endpoints News|
Sanofi nixes Kymab-originated OX40L antibody in atopic dermatitisnews2026-07-24T10:34:52+00:00July 24th, 2026|Endpoints News|
Gene editor Scribe starts second-half IPO spree with $129M listingnews2026-07-24T02:01:48+00:00July 24th, 2026|Endpoints News|
FDA adcomm votes in favor of lifting restrictions on popular wellness peptide BPC-157news2026-07-23T18:34:12+00:00July 23rd, 2026|Endpoints News|
FDA to end pilot aimed at preventing production issuesnews2026-07-23T18:24:20+00:00July 23rd, 2026|Endpoints News|